Clinical Trial Update: Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is studying the combination of cabozantinib and dostarlimab for recurrent gynecologic carcinosarcoma, and recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Gynecologic Cancer
• Uterine Carcinosarcoma

Drugs mentioned

• Cabometyx (cabozantinib)
• JEMPERLI (DOSTARLIMAB)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Gynecologic Cancer, Carcinoma | Phase 1, Phase 2 | Status: RECRUITING